RU95122782A - PHARMACEUTICAL PREPARATIONS CONTAINING NUCLEIC ACIDS - Google Patents

PHARMACEUTICAL PREPARATIONS CONTAINING NUCLEIC ACIDS

Info

Publication number
RU95122782A
RU95122782A RU95122782/13A RU95122782A RU95122782A RU 95122782 A RU95122782 A RU 95122782A RU 95122782/13 A RU95122782/13 A RU 95122782/13A RU 95122782 A RU95122782 A RU 95122782A RU 95122782 A RU95122782 A RU 95122782A
Authority
RU
Russia
Prior art keywords
dna construct
subject
plasmids
influenza virus
dna
Prior art date
Application number
RU95122782/13A
Other languages
Russian (ru)
Other versions
RU2193065C2 (en
Inventor
Дж.Доннелли Джон
Дж.Дварки Варавани
А.Лиу Маргарет
Л.Монтгомери Донна
Е.Паркер Сьюзанн
В.Шивер Джон
Б.Алмер Джеффри
Original Assignee
Мерк Энд Ко., Инк.
Викал Инкорпорейтед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Энд Ко., Инк., Викал Инкорпорейтед filed Critical Мерк Энд Ко., Инк.
Priority to RU95122782/13A priority Critical patent/RU2193065C2/en
Priority claimed from RU95122782/13A external-priority patent/RU2193065C2/en
Publication of RU95122782A publication Critical patent/RU95122782A/en
Application granted granted Critical
Publication of RU2193065C2 publication Critical patent/RU2193065C2/en

Links

Claims (10)

1. Конструкция ДНК, содержащая ген нуклеопротеина вируса гриппа, оперативно соединенный с регуляторной последовательностью, причем эта конструкция ДНК способна индуцировать специфический для вируса гриппа иммунный ответ при введении конструкции ДНК в клетки животных in vivo и регуляторная последовательность является иной, чем вектор вируса птичьего лейкоза и вектор вируса птичьей оспы.1. A DNA construct containing an influenza virus nucleoprotein gene operably linked to a regulatory sequence, this DNA construct capable of inducing an influenza virus-specific immune response when introducing a DNA construct into animal cells in vivo and the regulatory sequence is different than avian leukemia virus vector and Vector of smallpox virus. 2. Конструкция ДНК п.1, отличающаяся тем, что выбрана из
плазмиды pn RSU-PR-NP;
плазмиды U1-PR-NP;
плазмиды U1Jneo-NJ-NP;
плазмиды U1Jneo-TX-NP;
плазмиды U1Jns-BJ-NP; и
плазмиды U1Jns-PA-NP (B/Panama 45/90).2. DNA construction of claim 1, characterized in that it is selected from
plasmids pn RSU-PR-NP;
plasmids U1-PR-NP;
plasmids U1Jneo-NJ-NP;
plasmids U1Jneo-TX-NP;
plasmids U1Jns-BJ-NP; and
plasmids U1Jns-PA-NP (B / Panama 45/90). 3. Иммуногенная композиция, состоящая из конструкции ДНК п.1. 3. Immunogenic composition consisting of the DNA construct of claim 1. 4. Иммуногенная композиция, состоящая из конструкции ДНК п. 2. 4. Immunogenic composition consisting of the DNA construct of p. 2. 5. Вакцина, состоящая из конструкции ДНК п.1. 5. A vaccine consisting of the DNA construct of claim 1. 6. Вакцина, состоящая из конструкции ДНК п.2. 6. A vaccine consisting of the DNA construct of p.2. 7. Способ индуцирования специфического для вируса гриппа иммунного ответа в субъекте, отличающийся тем, что предусматривает обработку субъекта конструкцией ДНК п.1. 7. A method of inducing an influenza virus-specific immune response in a subject, characterized in that the subject is treated with a DNA construct of claim 1. 8. Способ индуцирования специфического для вируса гриппа иммунного ответа в субъекте, отличающийся тем, что предусматривает обработку субъекта конструкцией ДНК п.2. 8. A method of inducing an influenza virus-specific immune response in a subject, characterized in that the subject is treated with a DNA construct of claim 2. 9. Способ вакцинации субъекта, отличающийся тем, что предусматривает обработку субъекта конструкцией ДНК п.1. 9. The method of vaccination of the subject, characterized in that it provides for the processing of the subject with DNA construction of claim 1. 10. Способ вакцинации субъекта, отличающийся тем, что предусматривает обработку субъекта конструкцией ДНК п.2. 10. A method for vaccinating a subject, characterized in that it involves treating a subject with the DNA construct of claim 2.
RU95122782/13A 1994-03-14 1994-03-14 Dna structure (variants), dna-vector, immunogenic composition against influenza virus, method of immune response induction, vaccine and method of vaccination RU2193065C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU95122782/13A RU2193065C2 (en) 1994-03-14 1994-03-14 Dna structure (variants), dna-vector, immunogenic composition against influenza virus, method of immune response induction, vaccine and method of vaccination

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US089985 1993-07-08
US032383 1993-07-08
RU95122782/13A RU2193065C2 (en) 1994-03-14 1994-03-14 Dna structure (variants), dna-vector, immunogenic composition against influenza virus, method of immune response induction, vaccine and method of vaccination

Publications (2)

Publication Number Publication Date
RU95122782A true RU95122782A (en) 1998-02-27
RU2193065C2 RU2193065C2 (en) 2002-11-20

Family

ID=20175349

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95122782/13A RU2193065C2 (en) 1994-03-14 1994-03-14 Dna structure (variants), dna-vector, immunogenic composition against influenza virus, method of immune response induction, vaccine and method of vaccination

Country Status (1)

Country Link
RU (1) RU2193065C2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2570758T3 (en) * 2005-04-21 2016-05-20 Univ Florida Materials and methods for the control of respiratory diseases in canids
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
RU2520081C2 (en) * 2005-10-19 2014-06-20 Юниверсити Оф Флорида Рисерч Фаундейшн, Инк Flu virus, capable of infecting canidae and its application
JP2010526787A (en) * 2007-05-11 2010-08-05 ワクチン プロジェクト マネジメント ゲーエムベーハー Composition containing HCMV particles

Similar Documents

Publication Publication Date Title
Webster et al. Protection of ferrets against influenza challenge with a DNA vaccine to the haemagglutinin
Baxby et al. Potential use of non-replicating vectors as recombinant vaccines
Fynan et al. Use of DNA encoding influenza hemagglutinin as an avian influenza vaccine
Kodihalli et al. Cross-protection among lethal H5N2 influenza viruses induced by DNA vaccine to the hemagglutinin
Perkvs et al. Poxvirus‐based vaccine candidates for cancer, AIDS, and other infectious diseases
US5916879A (en) DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
CZ15999A3 (en) Formulation of polynucleotide vaccine of cats
RU2000116260A (en) LTB ADJUVANT VACCINES
DK0495896T3 (en) Vaccine for protection against HIV virus infections, methods for their preparation and use as diagnostic and immunotherapeutic agents
KR890700030A (en) Vaccines and diagnostic methods for influenza (Haemophilus influenzae)
DE3689622D1 (en) Vaccines against human respiratory viruses.
RU95122782A (en) PHARMACEUTICAL PREPARATIONS CONTAINING NUCLEIC ACIDS
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
Boyle Genus avipoxvirus
KR900701291A (en) Vaccines and diagnostic tests for hemophilus influenza
CN101220373B (en) Recombined viral vectors and uses thereof
EP1365799B1 (en) A novel vaccine formulation consisting of dna vaccine inactivated virus
SE8700466D0 (en) VACCINES AGAINST MELANOMA
Rott et al. Alterations in pathogenicity of influenza virus through reassortment.
Kasi Future Vaccines
Mikhael et al. Effectiveness Of The Pigeon Pox Vaccine On The Chicken Vaccinated With Avian Influenza Vaccine
RU92004487A (en) DNA, POLIPEPTID, VACCINE, VECTOR, MICROORGANISM, INSECTED CELL, REAGENT, METHODS OF TREATMENT AND PREVENTION, METHOD OF DETECTING ANTIGENES
Dietzschold et al. Synthesis of an antigenic determinant of the HSV gD that stimulates the induction of virus-neutralizing antibodies and confers protection against a lethal challenge of HSV.
Yilma et al. Attenuation of virulence and enhancement of immunogenicity.
Ghendon et al. Molecular-genetic analysis of the cold-adapted strain, a donor of attenuation for live influenza vaccine for children, of the recombinants produced on its basis, and of isolates from vaccinated children.